Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2004;328:1447-1448 (19 June), doi:10.1136/bmj.328.7454.1447
The evidence base for newer drug combinations and shorter regimens is weak
| The first 150 words of the full text of this article appear below. |
Leprosy still poses major therapeutic challenges. We have effective antibiotics to cure the infection, but the immune mediated peripheral nerve damage can continue long after effective antimicrobial treatment has started, and patients continue to be stigmatised. Effective management should therefore include treatment of nerve damage and reactions, prevention of disability, and reduction of stigma. The regimens recommended by the World Health Organization of six or 24 months' multidrug treatment (rifampicin, dapsone, and clofazimine) produce good clinical responses and low rates of relapse. The long term outcome for shorter regimens and other drug combinations, however, is not known. Testing for recent nerve damage and treating it with steroids is essential. Dermatologists already have an important role in treating patients in the large Indian and Brazilian cities, and this is likely to increase as leprosy programmes are integrated into primary care.
The WHO recommended multidrug regimen of rifampicin, clofazimine, and dapsone has
Diana N J Lockwood, consultant leprologist
Hospital for Tropical Diseases, London WC1E 6AU (diana.lockwood@lshtm.ac.uk)
Bhushan Kumar, professor of dermatology
Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India (kumarbhushan@hotmail.com)
Read all Rapid Responses